Back to today’s briefing

Story perspectives

FDA Approves Trials for Groundbreaking COVID Nasal Vaccine

2/7/2025

27 4

Summary

Story summary

The FDA has greenlit clinical trials for an innovative COVID-19 nasal vaccine from Washington University, spearheaded by Dr. Michael S. Diamond and Dr. David T. Curiel. Licensed to Ocugen, this promising vaccine seeks to enhance immunity and curb virus transmission, already in use in India since 2022. Results are anticipated within 12 to 18 months.

1 of 1

Story summary

The FDA has greenlit clinical trials for an innovative COVID-19 nasal vaccine from Washington University, spearheaded by Dr. Michael S. Diamond and Dr. David T. Curiel. Licensed to Ocugen, this promising vaccine seeks to enhance immunity and curb virus transmission, already in use in India since 2022. Results are anticipated within 12 to 18 months.